Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.160
-0.030 (-2.52%)
At close: Oct 30, 2026, 4:00 PM EDT
1.180
+0.020 (1.72%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Palisade Bio Revenue
Palisade Bio had revenue of $500.00K in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $500.00K. That makes Palisade Bio the 44,576th largest company in the world by revenue and 6,354th in the United States.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
404.31
Revenue / Employee
$35,714
Employees
14
Market Cap
202.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 250.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Compugen | 74.00M |
| Precision BioSciences | 45.06M |
| ProQR Therapeutics | 21.05M |
| Alpha Cognition | 15.26M |
| Pyxis Oncology | 11.04M |
| Upstream Bio | 3.16M |
| Korro Bio | 2.38M |
PALI News
- 3 days ago - Palisade Bio doses first patient in ASCENTRA-UC trial - TheFly
- 3 days ago - Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewsWire
- 11 days ago - Palisade Bio presents clinical, translational findings at UEG - TheFly
- 11 days ago - Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026 - GlobeNewsWire
- 23 days ago - Palisade Bio initiated with an Outperform at Raymond James - TheFly
- 4 weeks ago - Palisade Bio to present clinical, translational data for PALI-2108 at UEG Week - TheFly
- 4 weeks ago - Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 - GlobeNewsWire
- 5 weeks ago - Palisade Bio Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts